Sabatolimab (MBG453)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Sabatolimab (MBG453), covering 2026-01-07 to 2026-01-07. Get the full timeline:
Most recent: Clinical Trial Update: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [Phase 2]